• Journal of Pharmaceutical Investigation
• /
• v.8 no.1
• /
• pp.1-5
• /
• 1978

Drug interaction of a new antibiotic, methampicillin lysinate (MAL) with nine drugs were investigated using four species of gram positive and gram negative bacteria. The experimental results were as follows: 1. MIC of MAL were found to be decreased against E. coil when combined with mefenamic acid, probenecid, aluminium hydroxide gel or corticosteroids. The other drugs did not affect MIC of MAL against the same bacteria. 2. MIC of MAL were found to be increased against Staphylococcus aureus ATCC 6538-P, 9441 when combined with mefenamic acid, aluminum hydroxide gel or dexamethasone acetate. The other drugs did not affect MIC of MAL against the same bacteria. 3. MIC of MAL were found to be increased against Shigella dysenteriae when either of the nine drugs was combined. 4. MIC of MAL were found to be increased approximately 2.5 times when combined with Streptokinase-Streptodornase or hydrocortisone and to be decreased approximately 2 times when combined with probenecid or dexamethasone against Salmonella typhi(type 2). It seems the other drugs do not affect the MIC of MAL against the same bacteria.

• Microbiology and Biotechnology Letters
• /
• v.40 no.3
• /
• pp.180-185
• /
• 2012

Type 2 Diabetes Mellitus, a chronic metabolic disorder which results from a high blood glucose level, is one of the most prevalent and costly diseases of our time. Considering increasing rates of obesity and the aging population in Korea, the number of diabetic patients is likely to rise rapidly in the future. There are five conventional diabetic drugs which work through different mechanisms; sulfonylureas, biguanide, meglitinide, alpha-glucosidase inhibitors, and thiazolidinedione. Although they all have antidiabetic effects, some side effects such as hypoglycemia, weight gain and gastrointestinal intolerance are associated with them. Incretin based therapies, utilizing glucagon-like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which have a lower risk of adverse side effects, have recently been introduced. At present PPAR-targeting drugs are being actively developed. In this research review, particular emphasis has been placed on the current trends and possible biological targets for the new generation of antidiabetic drugs.

• Biomolecules & Therapeutics
• /
• v.18 no.3
• /
• pp.246-256
• /
• 2010

Atopic dermatitis is a common skin disease affecting up to 10% of children and approximately 2% of adults. Atopic dermatitis exhibits four major symptoms, including intense itching, dry skin, redness and exudation. The "itch-scratch-itch" cycle is one of the major features in atopic dermatitis. The pathophysiology and neurobiology of pruritus is unclear. Currently there are no single and universally effective pharmacological antipruritic drugs for treatment of atopic dermatitis. Thus, controlling of itch is a very important unmet need in patients suffering from atopic dermatitis. This article will update progress during the past 10 years of research in the field of pruritus of atopic dermatitis, focusing on aspects of pruritogens (including inflammatory lipids, histamine, serotonin, proteinases, proteinase-activating receptors, neurotransmitters, neuropeptides, and opioid peptides), antipruritic therapies, and emerging new targets. Based on recent progress, researchers expect to identify exciting possibilities for improved treatments and to develop new antipruritic drugs acting through novel targets, such as histamine H4 receptor, gastrin-releasing peptide receptor, MrgprA3, thromboxane A2 receptor and the putative SPC receptor.

• Biomolecules & Therapeutics
• /
• v.25 no.5
• /
• pp.461-470
• /
• 2017

Anticoagulant drugs, like vitamin K antagonists and heparin, have been the mainstay for the treatment and prevention of venous thromboembolic disease for many years. Although effective if appropriately used, traditional anticoagulants have several limitations such as unpredictable pharmacologic and pharmacokinetic responses and various adverse effects including serious bleeding complications. New oral anticoagulants have recently emerged as an alternative because of their rapid onset/offset of action, predictable linear dose-response relationships and fewer drug interactions. However, they are still associated with problems such as bleeding, lack of reversal agents and standard laboratory monitoring. In an attempt to overcome these drawbacks, key steps of the hemostatic pathway are investigated as targets for anticoagulation. Here we reviewed the traditional and new anticoagulants with respect to their targets in the coagulation cascade, along with their therapeutic advantages and disadvantages. In addition, investigational anticoagulant drugs currently in the development stages were introduced.

• Journal of Radiation Industry
• /
• v.7 no.2_3
• /
• pp.221-224
• /
• 2013

RI-Biomics is a new compound word of radiation technology and Biomics related to the study of life. RI-Biomics is high radiation fusion technology by combining evaluation of pharmacokinetics in vivo (RI-ADME) of new drugs and medical materials using radioisotope and molecular imaging technology using nuclear medicine equipments. RI-Biomics fields are emerging with the increasing usage of radioisotopes (RI). In this paper, we investigated the latest trends of radioisotope using in RI-Biomics fields. The representative radioisotopes are $^{14}C$, $^3H$ and $^{32}P$ for the optimization and the selection of candidates in the development process of new drugs among the RI-Biomics fields. As shown in the status of accumulated income of radioisotopes, using amounts of radioisotopes are showing a tendency to increase every year. $^{14}C$ is 61.6% increase of accumulated income growth rate and $^3H$ increased by 58.8% and $^{32}P$ increased by 33.9% in 2012 compared to 2007. These isotopes are used in a variety of fields as using of $^{14}C$ for microdosing test, development of [$^3H$]cholesterol absorption inhibitors, study of [$^{131}I$]pyronaridine tetraphosphate for malaria therapy. These are going on in vivo test sucessfully. So, clinical research step is expected to begin soon. Therefore, usages of radioisotopes are necessary and need for the evaluation of pharmacokinetics, optimization and the selection of new drug candidates in the development process of new drugs among the RI-Biomics fields. So, using of radioisotopes is predict to increase continuously except for primarily used $^{14}C$, $^3H$.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1996.04a
• /
• pp.197-197
• /
• 1996

Helicobacter pylori (H. pylori) is a microaerophilic spiral bacterium and infection by it in the human stomach causes gastritis, furthermore, it is considered to be involved in the pathogenesis of peptic ulcers and the development of gastric carcinoma. We assessed the inhibitory activity of new antiulcer drugs against Helicobacter pylori. The activities of new antiulcer agents against Helicobacter pylori strains were determined by the standard agar dilution method with blood agar base #2, supplemented with 5% sheep blood and 4 antibiotics to support growth of these organisms. They were inoculated by multipoint inoculator and incubated at 37$^{\circ}C$ for 3 days under microaerophilic atmosphere. The MIC of antiulcer agents was the lowest concentration that inhibited visible growth of these organisms. According to results of various biochemical tests, these bacteria were identified as Helicobacter pylori strains. And the MIC results showed that the strains were very susceptible to omeprazole and YJA20379s. Some of YJA20379s were more potent than omeprazole. These results suggest that our new antiulcer drugs have potent inhibitory activity against Helicobacter pylori, so that our new antiulcer drugs might be useful for the clinical eradication of gastrointestinal Helicobacter pylori.

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 1994.04a
• /
• pp.63-81
• /
• 1994

• Proceedings of the PSK Conference
• /
• 2000.04a
• /
• pp.43-44
• /
• 2000

• Proceedings of the Korean Society of Toxicology Conference
• /
• 2005.11a
• /
• pp.188-202
• /
• 2005

• Toxicological Research
• /
• v.8 no.2
• /
• pp.303-316
• /
• 1992